Table 18.8

Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival	(Dercent)								
Year of Diagnosis:	(rercent)								
1960-1963 ^a	_	_	_	12	13	10	_	_	_
1970-1973 ^a	_	_	_	19	20	17	_	_	_
1975-1977 ^b	24.6	23.9	25.3	24.1	23.6	24.7	29.3	28.9	29.5
1978-1980 ^b	25.9	24.4	27.5	24.8	24.1	25.5	32.5	27.4	37.5
1981-1983 ^b	27.5	25.7	29.4	27.2	25.4	28.9	28.9	29.6	27.9
1984-1986 ^b	27.2	27.6	26.9	25.9	25.7	26.2	31.8	33.3	30.3
1984-1980 1987-1989 ^b	27.2	28.9	25.5	26.9	29.1	24.5	30.0	33.3 29.7	30.3
1987-1989 1990-1992 ^b	29.2	30.5	27.9	28.3	29.1	26.9	34.3	38.1	30.5
									35.7
1993-1995 ^b	31.6	32.1	31.1	30.5	31.2	29.6	35.4	34.9	
1996-1998 ^b	32.4	34.5	30.3	32.2	34.2	29.8	31.4	33.0	30.2
1999-2001 ^b	34.4	36.7	31.8	34.4	36.8	31.5	34.1	36.7	32.0
2002-2005 ^b	43.2	44.1	42.2	43.6	45.1	41.7	42.3	41.1	43.5
2006-2012 ^b	50.2 ^f	50.4 ^f	50.1 ^f	49.8 ^f	50.6 ^f	48.9 ^f	51.8 ^f	49.7 ^f	53.7 ^f
5-Year Period Survival (F	Percent)cd								
2012	49.5	50.4	48.4	49.2	50.5	47.5	50.3	50.0	50.5
Stage Distribution (%) 20	006-2012 ^{ce}								
All Stages	20 406	16 660	10 566	00 140	10 500	0 616	6 000	0 006	2 1 4 4
Number of cases	30,426	16,660	13,766	22,149	12,533	9,616	6,080	2,936	3,144
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	6	4	5	6	4	4	5	3
Regional	0	0	0	0	0	0	0	0	0
Distant	95	94	96	95	94	96	96	95	97
Unstaged	0	0	0	0	0	0	0	0	0
5-Year Relative Survival	(Percent) 2	006-2012°							
Age at Diagnosis:	(10100110), 1	000 2012							
Ages <45	73.1	71.6	75.3	72.3	70.6	75.2	72.5	72.1	73.0
Ages 45-54	64.8	63.7	66.4	66.4	65.3	67.9	59.2	55.2	63.2
Ages 55-64	58.0	57.8	58.2	58.5	59.0	57.8	56.8	54.9	58.8
Ages 55-04 Ages 65-74	47.4	47.2	47.7	48.4	48.5	48.3	44.3	41.7	46.6
Ages 75+	29.2	30.4	28.1	29.5	31.1	28.0	26.7	28.3	26.0
Ages <65	61.7	61.1	62.5	62.3	62.1	62.5	59.5	57.1	62.0
Ages 65+	38.2	39.2	37.1	38.5	39.9	36.9	36.7	36.8	36.6
Stage ^e :									
All Stages	48.5	49.4	47.4	48.4	49.8	46.5	48.8	48.3	49.2
Localized	69.6	71.4	66.3	70.5	73.1	65.5	61.5	60.9 ^g	62.4 ^g
Regional	=		=	-	-	-	· · · -	_	· · · · =
Distant	47.4	48.1	46.6	47.1	48.3	45.7	48.3	47.7	48.8
Unstaged		-	-	-	-	-	-		-
onscayed									

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2013.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2013.

Period survival provides a 2012 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2008-2010: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^{(2009-2011: 1-2} year survival), (2006-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2006: 4-5 years survival).

Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2006-2012 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.